Medicare does cover Winrevair (sotatercept-csrk) for adults with pulmonary arterial hypertension, generally under the Part D prescription drug benefit. With a list price around $14,000 per vial and an estimated annual cost near $240,000, the practical question is what you actually pay out of pocket, and in 2026 the answer for most Part D enrollees is capped at $2,100 for the year.
How Medicare Pays for Winrevair
Winrevair is a subcutaneous injection given once every three weeks. The FDA-approved labeling allows patients or caregivers to self-inject at home after training from a healthcare provider, which is why it sits on the pharmacy side of Medicare rather than the physician-administered side for most people.1Winrevair.com. How to Take Winrevair
The coverage pathway still depends on your plan. Merck’s provider guidance states that “Medicare coverage for WINREVAIR depends on what type of Medicare plan the patient is enrolled in (standalone Medicare Part D or Medicare Advantage) and the benefits available under their specific Medicare plan.”2Merck Access Program. Winrevair Guide to Appeals and Medical Exceptions Some Medicare Advantage plans cover the drug under their medical benefit when a clinician administers it in an outpatient setting, with prior authorization required.
What You’ll Pay in 2026
The Inflation Reduction Act’s redesign of Part D is the single biggest factor in what a Winrevair patient owes. Beginning in 2025, the law capped annual out-of-pocket spending on Part D drugs. For 2026, that cap is $2,100. Once your out-of-pocket spending hits the cap, you pay nothing for covered Part D drugs for the rest of the calendar year.3Medicare.gov. Part D Costs4CMS. Final CY 2026 Part D Redesign Program Instructions
For a drug priced like Winrevair, here is how the stages play out in 2026:
- Deductible stage: you pay 100% of the cost until you meet your plan’s deductible, which can be up to $615.3Medicare.gov. Part D Costs
- Initial coverage stage: you generally pay 25% coinsurance. Given the per-dose price, one or two fills push most patients past the $2,100 cap.
- Catastrophic stage: once you hit $2,100, you pay $0 for covered Part D drugs for the rest of the year.
In practice, a Part D enrollee starting Winrevair will likely reach the annual cap within the first month or two of treatment, and the remaining doses that year carry no additional cost. If paying $2,100 at the front of the year is a strain, the Medicare Prescription Payment Plan lets you spread that spending across the calendar year instead of paying it all at once.3Medicare.gov. Part D Costs
Specialty-tier coinsurance before the cap varies by plan. A Kaiser Family Foundation analysis found that median specialty-tier coinsurance is 25% for standalone Part D enrollees and 30% for Medicare Advantage drug plan enrollees.5KFF. Medicare Part D in 2025: A First Look at Prescription Drug Plan Availability, Premiums, and Cost Sharing Because the cap applies regardless, the practical ceiling on your yearly spending is still $2,100.
Prior Authorization Requirements
Nearly every Part D and Medicare Advantage plan requires prior authorization before covering Winrevair. Criteria vary by insurer, but common requirements include:
- A confirmed WHO Group 1 PAH diagnosis documented by right heart catheterization
- Age 18 or older
- Concurrent use of at least two other PAH drug classes, such as endothelin receptor antagonists, PDE-5 inhibitors, or prostacyclin analogues6PA Health & Wellness (Centene). Sotatercept (Winrevair) Clinical Policy
- An adequate platelet count, commonly at least 50 × 10⁹/L
- Prescription from, or in consultation with, a cardiologist or pulmonologist
Some insurers use risk-based criteria instead. Cigna’s policy, updated in June 2026, bases approval on whether the prescriber classifies the patient as intermediate-high or high risk, which allows approval without additional step therapy, or as low or intermediate-low risk, which requires at least 60 days of prior PAH therapy.7Cigna. Coverage Position Criteria: Pulmonary Arterial Hypertension – Winrevair
If Your Plan Denies Coverage
A denial is not the end of the road. Your prescriber can submit a formulary exception request with a letter of medical necessity and supporting documentation such as catheterization results, functional status, and the history of prior therapies. Plans must respond within 72 hours for standard requests and 24 hours for expedited ones.2Merck Access Program. Winrevair Guide to Appeals and Medical Exceptions
If the exception is denied, you can pursue Medicare’s multi-level appeals process. The first level is a redetermination by the plan, which must be filed within 60 days of the denial. If that fails, the case goes to an independent review entity, then an administrative law judge, then the Medicare Appeals Council, and ultimately federal court. Each level generally has a 60-day filing deadline from the prior decision.8Patient Advocate Foundation. Medicare Denials and Appeals
The Merck Access Program offers appeal letter templates and benefits investigation support. Providers can reach the program at 888-637-2502.9Merck Access Program. Coverage and Reimbursement
Help Paying the Out-of-Pocket Share
Spending $2,100 on one medication is still significant. One route most Medicare patients cannot take: Merck’s copay card is available only to commercially insured patients, not people with Medicare or other government coverage.10Merck. Merck Access Program for Winrevair Merck’s separate patient assistance program through MerckHelps.com provides the medication free of charge, but eligibility generally requires having no insurance coverage for the drug; Medicare patients may qualify only by demonstrating financial and medical hardship and meeting income limits.11MerckHelps. Winrevair Patient Assistance
Independent nonprofit foundations fill the gap for Medicare enrollees:
- HealthWell Foundation’s PH Medicare Access Fund, open as of mid-2026, lists Winrevair as a covered treatment and provides grants up to $6,500 for prescription copays or Part B premiums. Income must be at or below 500% of the federal poverty level.12HealthWell Foundation. Pulmonary Hypertension – Medicare Access
- The PAN Foundation offers pulmonary hypertension copay grants with an initial grant of $9,500 and a maximum annual benefit up to $13,500, accepts all insurance types including Medicare, and uses the same 500% FPL income threshold.13PAN Foundation. Pulmonary Hypertension Fund
- The Assistance Fund accepts all insurance types for its pulmonary hypertension copay program; as of mid-2026 it is taking waitlist applications rather than immediate enrollment.14The Assistance Fund. Pulmonary Hypertension Copay Assistance Program
- Medicare’s Extra Help program assists lower-income beneficiaries with Part D premiums, deductibles, and copays. Call Social Security at 800-772-1213 for details.15Pulmonary Hypertension Association. Insurance and Financial Assistance Resources
Fund availability changes often. The PAN Foundation’s FundFinder tool and the Pulmonary Hypertension Association’s resource page track which programs are currently open.15Pulmonary Hypertension Association. Insurance and Financial Assistance Resources